Daniel Kuhn is computational chemist at Merck Healthcare. After studying pharmacy, he obtained his PhD from Philipps-University, Marburg working with Gerhard Klebe on the classification of protein binding sites. In 2004 he joined Boehringer Ingelheim in Vienna as computational chemist working in oncology research. In 2010 he joined Merck as principal scientist contributing to projects in early and late drug discovery stages. He successfully led a project from hit identification phase to preclinical development. His research interests include the combination of structure-based approaches (e.g. FEP) with predictive modelling in hit and lead optimization and how predictive models can be efficiently communicated to Merck scientists.